Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2022.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].
Eur Urol
September 2024
Sutter Cancer Center (accruals under Radiological Associates of Sacramento), Sacramento, CA, USA.
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer.
Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of androgen deprivation therapy (ADT)Â +Â external beam radiation therapy (EBRT)Â +Â docetaxel with ADTÂ +Â EBRT.
Design, Setting, And Participants: High-risk localized prostate cancer patients (>50% of patients had Gleason 9-10 disease) were prospectively randomized to 2 yr of ADTÂ +Â EBRT or ADTÂ +Â EBRTÂ +Â six cycles of docetaxel.
Corrigendum to Journal of Pharmaceutical Sciences Volume 110 (2021) 2946-2954.
J Pharm Sci
June 2024
Department of Neurosurgery, School of Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, People's Republic of China. Electronic address:
Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Front Immunol
March 2024
Laboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montréal, QC, Canada.
[This corrects the article DOI: 10.3389/fimmu.2024.
View Article and Find Full Text PDFCorrigendum to "Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer".
J Pharm Sci
April 2024
Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. Electronic address:
Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821].
Neoplasia
December 2022
Department of Pathology, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University. 170 Xinsong Rd, Shanghai, China. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!